MEDIFAST (NYSE:MED) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Key Points

• MEDIFAST reported earnings of $0.04 EPS for the quarter, surpassing expectations by $0.26, and also provided updated guidance for Q3 2025, indicating a potential EPS between -0.600 and 0.00.
• The company's stock declined by 1.8% to $13.50, amidst a trading volume of 145,054 shares, which is below its average of 207,095 shares.
• Wall Street Zen upgraded MEDIFAST from a "hold" to a "buy" rating, signaling increased confidence in the company's future performance.

MEDIFAST (NYSE:MED - Get Free Report) announced its earnings results on Monday. The specialty retailer reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.26, Zacks reports. MEDIFAST had a negative net margin of 1.29% and a positive return on equity of 6.63%. MEDIFAST updated its Q3 2025 guidance to -0.600-0.00 EPS.

MEDIFAST Trading Down 1.8%

NYSE MED traded down $0.25 during trading on Monday, reaching $13.50. The company's stock had a trading volume of 145,054 shares, compared to its average volume of 207,095. The firm has a market capitalization of $148.37 million, a price-to-earnings ratio of -20.77 and a beta of 0.80. MEDIFAST has a 12 month low of $11.57 and a 12 month high of $21.98. The firm has a 50 day moving average price of $13.93 and a 200 day moving average price of $13.96.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of MEDIFAST from a "hold" rating to a "buy" rating in a report on Thursday, May 1st.

Institutional Trading of MEDIFAST

A number of institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new position in MEDIFAST during the 1st quarter worth approximately $78,000. Amundi increased its position in MEDIFAST by 43.5% during the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer's stock worth $398,000 after purchasing an additional 9,224 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in MEDIFAST by 14.5% during the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer's stock worth $2,693,000 after purchasing an additional 25,366 shares in the last quarter. Institutional investors own 95.51% of the company's stock.

About MEDIFAST

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.